> Biologics and Pregnancy | BiologicHealthPlus>

Biologics and Pregnancy

What to know before, during, and after pregnancy while on biologic therapy

⚠️ Important

Never stop or start any biologic medication during pregnancy without consulting your rheumatologist, gastroenterologist, or OB/GYN. This page provides general educational information only — your care team will make individualized recommendations based on your specific condition, medication, and pregnancy timing.

Key Takeaways

  • Uncontrolled autoimmune disease during pregnancy carries significant risks to mother and fetus
  • Some biologics have more safety data in pregnancy than others
  • Timing of doses relative to delivery may affect newborn immune function
  • Cimzia (certolizumab pegol) has the lowest known placental transfer among TNF inhibitors
  • All decisions should be made collaboratively with your specialist

Biologics and Placental Transfer

IgG antibody-based biologics (most monoclonal antibodies) cross the placenta via the FcRn receptor, with transfer increasing significantly in the second and third trimesters. This means the newborn may have detectable biologic levels at birth and for weeks to months afterward, which has implications for timing of the mother's last dose and the newborn's vaccine schedule (live vaccines should typically be delayed).

MedicationPlacental TransferGeneral Guidance
Cimzia (certolizumab)Minimal (PEGylated Fab, no Fc region)Often considered when pregnancy is planned; discuss with specialist
Humira (adalimumab)High in 3rd trimesterSome specialists stop last dose by week 34; individualized
Remicade (infliximab)High in 3rd trimesterIndividualized timing — discuss with gastroenterologist/rheumatologist
Entyvio (vedolizumab)ModerateGut-selective; some data supports continued use; specialist guidance needed
Rinvoq / Xeljanz (JAK inhibitors)Cross placentaGenerally not recommended in pregnancy — discuss stopping before conception
Do not stop your biologic without consulting your specialist. Uncontrolled autoimmune disease during pregnancy carries risks including preterm birth, low birth weight, and maternal complications. Your rheumatologist, gastroenterologist, or dermatologist will weigh the risks and benefits of continuing, modifying, or stopping your biologic based on your specific situation.
Cimzia (certolizumab pegol) has the lowest known placental transfer among approved biologics, due to its unique PEGylated Fab structure that lacks an Fc region. Studies show minimal to no detectable Cimzia in cord blood at delivery. For this reason, some specialists transition patients to Cimzia when pregnancy is planned, though this decision should always be individualized.
Most large-molecule biologics (monoclonal antibodies) have very limited transfer into breast milk and are poorly absorbed orally by infants, suggesting minimal systemic exposure to the infant. However, data varies by medication and breastfeeding guidance should be discussed with your specialist and a lactation consultant. See our biologics and breastfeeding guide.

💊 BiologicHealthPlus Supports You Through Pregnancy

We work closely with your care team to coordinate biologic supply, timing, and insurance coverage throughout your pregnancy. Our pharmacists are available 24/7.

Talk to a Pharmacist →

📚 Sources & Further Reading

Content developed with reference to leading health organizations, peer-reviewed research, and FDA prescribing information.

🔗
Reproductive Health GuidelinesACR
🔗
Biologics in PregnancyMotherToBaby
🔗
Placental TransferWikipedia
🔗
Biologics & Pregnancy ReviewNIH/NCBI

Medical Disclaimer: Educational content reviewed by the BiologicHealthPlus Clinical Team. Consult your healthcare provider for personalized advice. Last reviewed: August 2026.

Medical Disclaimer: This page provides general educational information only. All pregnancy-related biologic decisions must be made with your healthcare providers. Last updated: July 2026.